NASDAQ:IFRX InflaRx Q4 2025 Earnings Results & Report $1.15 -0.03 (-2.54%) Closing price 04:00 PM EasternExtended Trading$1.12 -0.03 (-2.52%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. InflaRx met analyst earnings expectations and missed on revenue in its Q4 2025 results, released March 20, 2026. The company reported EPS of -$0.17 versus the -$0.17 consensus estimate, while revenue of -$39.83 thousand fell short of the $26 thousand estimate by $65.83 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 20, 2026TimeBefore Market OpensConference Call DateMarch 19, 2026Conference Call9:30 AM ET InflaRx EPS ResultsActual EPS-$0.17Consensus EPS -$0.17Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersInflaRx Revenue ResultsActual Revenue-$39.83 thousandExpected Revenue$26 thousandBeat/MissMissed by -$65.83 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) InflaRx Q4 2025 Earnings FAQ Did InflaRx beat earnings estimates for Q4 2025? InflaRx (NASDAQ:IFRX) reported earnings of -$0.17 per share for Q4 2025, matching the consensus estimate of -$0.17. The report was announced on Friday, March 20, 2026. What was InflaRx's revenue for Q4 2025? InflaRx reported revenue of -$39.83 thousand for Q4 2025, against a consensus estimate of $26 thousand. InflaRx Earnings HeadlinesHere's why InflaRx (IFRX) is a great buy the bottom stock nowNovember 13, 2026 | msn.comInflaRx Publishes First-In-Human Phase 1 Results For Izicopan; Stock UpNovember 9, 2026 | rttnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 17 at 1:00 AM | Weiss Ratings (Ad)InflaRx (IFRX) AI Stock AnalysisNovember 7, 2026 | tipranks.comInflaRx Stock Gets Stronger EPS Forecast from HC WainwrightNovember 7, 2026 | americanbankingnews.comInflaRx Highlights Positive Phase 1 Findings For Oral Drug Candidate Izicopan; Stock DownNovember 6, 2026 | rttnews.comSee More InflaRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email. Email Address About InflaRxInflaRx (NASDAQ:IFRX) is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions. Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.View InflaRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.